Skip to main
IDYA

IDYA Stock Forecast & Price Target

IDYA Analyst Ratings

Based on 14 analyst ratings
Buy
Strong Buy 36%
Buy 57%
Hold 7%
Sell 0%
Strong Sell 0%

Bulls say

IDEAYA Biosciences is poised for success with its innovative approach to targeted oncology therapies and strong clinical data from its ongoing trials. Their multiple clinical-stage product candidates, including darovasertib and IDE849, have shown impressive efficacy in their respective clinical trials, with consistent PFS improvements across all patient subgroups and a manageable safety profile. With upcoming milestones such as the full dataset from the Phase 2/3 OptimUM-02 trial and a potential full approval for one of their candidates, IDYA is well-positioned for continued growth and its current valuation does not fully reflect its potential in the precision medicine market.

Bears say

IDEAYA Biosciences is trading at a premium due to its promising clinical-stage product candidates, but its risks include potential setbacks in R&D and regulatory approval, as well as competition from emerging companies. Additionally, lower than expected product sales and the need for dilutive financing could also be potential concerns for the company's financial outlook. These factors contribute to the analyst's negative outlook on the stock.

IDYA has been analyzed by 14 analysts, with a consensus rating of Buy. 36% of analysts recommend a Strong Buy, 57% recommend Buy, 7% suggest Holding, 0% advise Selling, and 0% predict a Strong Sell.

This aggregate rating is based on analysts' research of Ideaya Biosciences Inc and is not a guaranteed prediction by Public.com or investment advice.

Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy

FAQs About Ideaya Biosciences Inc (IDYA) Forecast

Analysts have given IDYA a Buy based on their latest research and market trends.

According to 14 analysts, IDYA has a Buy consensus rating as of Jun 26, 2026. This rating is provided by third-party analysts and is not investment advice from Public.com.

Wall Street analysts have set a price target of $53.14, reflecting a 0.00% increase from the current stock price.

Financial analysts have set a price target of $53.14, indicating a 0.00% increase from the current stock price, but ratings and forecasts are frequently updated based on market conditions, earnings reports, and industry trends. This prediction is provided by third-party analysts and is not investment advice from Public.com.

Ideaya Biosciences Inc (IDYA)


Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy
Disclaimer: Any investment listed here, which may be available on the Public platform, is intended to be used for informational purposes only, should not be the sole basis for making an investment decision, and is not a recommendation or advice.